Bahrain Approves Oxford-AstraZeneca COVID Vaccine for Emergency Use

Bahrain has approved the Oxford-AstraZeneca COVID-19 vaccine manufactured at the Serum Institute of India (SII) for emergency use, state news agency BNA reported on Monday, citing the country's National Health Regulatory Authority.
The
vaccine is the third to be approved by Bahrain for emergency use following
SinoPharma and Pfizer and Biontech.
Monday’s
announced approval was based on the study carried out by the National Health
Regulatory Authority with the participation of NHRA's Clinical Research
Committee and the Ministry of Health's Immunization Committee.
The
study considered data from AstraZeneca about the results of studies on the
vaccine conducted in several countries, immunity data and the manufacturing
data provided by SII to prove the process complies with international standards.
NHRA
Chief Executive Officer Dr. Mariam Adhbi Al Jalahma said an in-depth study of
all the data submitted by IIS, including the quality of manufacturing and the
results of the immunity study had been conducted.
She
pointed out that NHRA approved the emergency use in coordination with the
manufacturer because it applies to many procedures for controlling the quality,
safety and effectiveness of the vaccine.
They include use within a range determined by the health authorities in Bahrain, deciding the numbers of target groups, the dose and the vaccination system, and providing information supporting safety, efficiency and manufacturing.